This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeoStem Announces Grant Of Two U.S. Patents For CD34 Cell Program

NEW YORK, May 27, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, today announced the expansion of intellectual property protection surrounding its CD34 Cell Program. That program is developing therapeutics to address ischemia, the process that occurs when the supply of oxygenated blood in the body is restricted. The recently granted U.S. patents relate to AMR-001, the Company's most clinically advanced product candidate in its CD34 Cell Program, which is designed to treat damaged heart muscle following acute myocardial infarction (AMI or heart attack).

United States patents 8,637,005 and 8,709,403 are entitled "Compositions and Methods of Vascular Injury Repair" and serve to further expand the range of serum concentrations used to deliver CD34 cells from claims of previously granted patents. These patents bring the total number of granted and allowed patents for the Company's CD34 cell program to 16. 

Heart attacks and cardiovascular disease are a significant physical and economic burden on society. If approved by the FDA and other worldwide regulatory agencies, AMR-001 for AMI patients could address significant unmet medical need in the treatment of cardiovascular disease around the world. AMI patients are at significant risk of downstream adverse events, including chronic heart failure, re-current AMI, significant arrhythmias, premature death or acute coronary syndrome. A statistical report from Agency for Healthcare Research and Quality (2011) surveyed the most expensive hospitalization conditions by payer and lists AMI as the sixth most expensive condition treated in U.S. hospitals, with a national hospital bill of more than $37 billion annually.

"As we continue to develop our therapeutic candidates, advancement in our intellectual property profile, in the U.S. and globally, expands the potential for partnership discussions," said Dr. Robin Smith, Chairman and CEO of NeoStem.

NeoStem is increasing its patent portfolio for its CD34 Cell Program both domestically and internationally, including recent patent grants in the European Union, Japan, Canada, Russia, Malaysia, and the Philippines. In Q4 2013 the Company announced completion of enrollment in its Phase 2 PreSERVE AMI clinical trial, a randomized, double-blind placebo-controlled study testing AMR-001for the treatment of patients with left ventricular dysfunction following ST segment elevation myocardial infarction ("STEMI"). Data read-out is expected in 2H 2014 and the Company expects to advance the technology into other clinical indications such as chronic heart failure, traumatic brain injury and/or critical limb ischemia.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,263.77 -21.97 -0.12%
S&P 500 2,129.46 -1.36 -0.06%
NASDAQ 5,093.0570 +2.2630 0.04%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs